Arcus Biosciences, Inc. beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging +8.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.98 | $-0.72 | +26.5% | Beat | Q2 FY26 call |
| Q1 FY26 | $-0.92 | $-1.02 | -10.9% | Miss | |
| Q4 FY25 | $-1.11 | $-0.89 | +19.8% | Beat | Q4 FY25 call |
| Q3 FY25 | $-1.33 | $-1.27 | +4.5% | Beat | |
| Q2 FY25 | $-1.14 | $0.00 | +100.0% | Beat | |
| Q1 FY25 | $-1.02 | $-1.14 | -11.8% | Miss | |
| Q4 FY24 | $-1.17 | $-1.03 | +12.0% | Beat | |
| Q3 FY24 | not reported | $1.00 | not reported | not reported | |
| Q2 FY24 | $-1.02 | $-1.02 | +0.0% | Beat | |
| Q1 FY24 | not reported | $-0.05 | not reported | not reported | |
| Q4 FY23 | $-1.09 | $-1.08 | +0.9% | Beat | |
| Q3 FY23 | $-1.12 | $-0.94 | +16.1% | Beat |
Back to RCUS overview · RCUS holders · RCUS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.